Piper Sandler Reiterates Overweight Rating on Amphastar Pharmaceuticals (AMPH)
Tweet Send to a Friend
Piper Sandler analyst David Amsellem reiterated an Overweight rating and $71.00 price target on Amphastar Pharmaceuticals (NASDAQ: AMPH).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


